Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

The treatment of pediatric chronic myelogenous leukemia in the imatinib era

  • Lee, Jae-Wook (Department of Pediatrics, The Catholic University of Korea College of Medicine) ;
  • Chung, Nack-Gyun (Department of Pediatrics, The Catholic University of Korea College of Medicine)
  • Received : 2010.02.16
  • Accepted : 2010.03.07
  • Published : 2011.03.15
Download PDF
⟨ Previous Next ⟩

Abstract

Childhood chronic myelogenous leukemia (CML) is a rare hematologic disease, with limited literature on the methods of treatment. Previously, allogeneic hematopoietic stem cell transplantation (HSCT) was considered the only curative treatment for this disease. Treatment with imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase (TKI), has resulted in prolonged molecular response with limited drug toxicity. Imatinib is now implemented in the primary treatment regimen for children, but the paucity of evidence on its ability to result in permanent cure and the potential complications that may arise from long-term treatment with TKIs have prevented imatinib from superseding HSCT as the primary means of curative treatment in children. The results of allogeneic HSCT in children with CML are similar to those observed in adults; HSCT-related complications such as transplant-related mortality and graft-versus-host disease remain significant challenges. An overall consensus has been formed with regards to the need for HSCT in patients with imatinib resistance or those with advanced-phase disease. However, issues such as when to undertake HSCT in chronic-phase CML patients or how best to treat patients who have relapsed after HSCT are still controversial. The imatinib era calls for a reevaluation of the role of HSCT in the treatment of CML. Specific guidelines for the treatment of pediatric CML have not yet been formulated, underscoring the importance of prospective studies on issues such as duration of imatinib treatment, optimal timing of HSCT and the type of conditioning utilized, possible treatment pre-and post-HSCT, and the role of second-generation TKIs.

Keywords

References

  1. Altman AJ. Chronic leukemias of childhood. Pediatr Clin North Am 1988;35:765-87.
  2. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497
  3. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia. Nature 1973;243:290-3. https://doi.org/10.1038/243290a0
  4. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40. https://doi.org/10.1056/NEJM199904293401706
  5. Millot F, Traore P, Guilhot J, Nelken B, Leblanc T, Leverger G, et al. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics 2005;116:140-3. https://doi.org/10.1542/peds.2004-2473
  6. Vardiman JW, Melo JV, Baccarani M, Thiele J. Chronic myelogenous leukemia, BCR-ABL1 positive. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of hematopoietic and lymphoid tissues. Lyon:IARC, 2008:32-7.
  7. Suttorp M, Yaniv I, Schultz KR. Controversies in the treatment of CML in children and adolescents: TKIs versus BMT? Biol Blood Marrow Transplant 2011;17(1 Suppl):S115 -22. https://doi.org/10.1016/j.bbmt.2010.09.003
  8. Apperley J. CML in pregnancy and childhood. Best Pract Res Clin Haematol 2009;22:455-74. https://doi.org/10.1016/j.beha.2009.09.008
  9. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-51. https://doi.org/10.1200/JCO.2009.25.0779
  10. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al; The German CML Study Group. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. Blood 1993;82:398-407.
  11. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, et al; French Chronic Myeloid Leukemia Study Group. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997;337:223-9. https://doi.org/10.1056/NEJM199707243370402
  12. Kantarjian HM, O'Brien S, Smith TL, Rios MB, Cortes J, Beran M, et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukaemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol 1999;17:284-92. https://doi.org/10.1200/JCO.1999.17.1.284
  13. Arthur CK, Ma DD. Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia. Acta Haematol 1993;89 Suppl 1:15-21. https://doi.org/10.1159/000204580
  14. Millot F, Guilhot J, Nelken B, Leblanc T, Leverger G, Bernard F, et al. Results of a phase II trial testing interferon-alpha 2b and cytarabine in children and adolescents with chronic myelogenous leukemia. Pediatr Blood Cancer 2006;47:555-9. https://doi.org/10.1002/pbc.20586
  15. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17. https://doi.org/10.1056/NEJMoa062867
  16. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6. https://doi.org/10.1038/nm0596-561
  17. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004. https://doi.org/10.1056/NEJMoa022457
  18. Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood 2004;104:2655-60. https://doi.org/10.1182/blood-2003-09-3032
  19. Suttorp M, Millot F. Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation. Hematology Am Soc Hematol Educ Program 2010;2010:368-76. https://doi.org/10.1182/asheducation-2010.1.368
  20. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999;131:207-19. https://doi.org/10.7326/0003-4819-131-3-199908030-00008
  21. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesTM). Chronic myelogenous leukemia. Available from: www.nccn.org/index.asp. [Accessed February, 2011.]
  22. Suttorp M. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT. Bone Marrow Transplant 2008;42 Suppl 2:S40-6. https://doi.org/10.1038/bmt.2008.282
  23. Zwaan CM, Rizzari C, van der Velden VHJ, Beverloo B, den Boer ML, Baruchel A, et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: interim results of the CA180-018 phase I study from the ITCC consortium. Blood 2008;112:3241a
  24. Millot F, Guilhot J, Nelken B, Leblanc T, De Bont ES, Bekassy AN, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia 2006;20:187-92. https://doi.org/10.1038/sj.leu.2404051
  25. Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM, et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 2008;50:254-8. https://doi.org/10.1002/pbc.21132
  26. Mauro MJ, Deininger MW. Management of drug toxicities in chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009;22:409-29. https://doi.org/10.1016/j.beha.2009.06.001
  27. Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y, et al. Imatinib is efficient but has a negative impact on growth in children with previously untreated chronic myelogenous leukaemia (CML) in early chronic phase (CP): results of the French national phase IV trial. Blood 2009;114:863a.
  28. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354:2006-13. https://doi.org/10.1056/NEJMoa051140
  29. Kimoto T, Inoue M, Kawa K. Growth deceleration in a girl treated with imatinib. Int J Hematol 2009;89:251-2. https://doi.org/10.1007/s12185-008-0251-8
  30. Vandyke K, Dewar AL, Fitter S, Menicanin D, To LB, Hughes TP, et al. Imatinib mesylate causes growth plate closure in vivo. Leukemia 2009;23:2155-9. https://doi.org/10.1038/leu.2009.150
  31. Mariani S, Giona F, Basciani S, Brama M, Gnessi L. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. Lancet 2008;372:111-2. https://doi.org/10.1016/S0140-6736(08)61023-5
  32. Shah NP. Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program 2005:183-7.
  33. Suttorp M, Claviez A, Bader P, Peters C, Gadner H, Ebell W, et al. Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I. Klin Padiatr 2009;221:351-7. https://doi.org/10.1055/s-0029-1239529
  34. Millot F, Esperou H, Bordigoni P, Dalle JH, Michallet M, Michel G, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant 2003;32:993-9. https://doi.org/10.1038/sj.bmt.1704255
  35. Cwynarski K, Roberts IA, Iacobelli S, van Biezen A, Brand R, Devergie A, et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood 2003;102:1224-31. https://doi.org/10.1182/blood-2002-12-3637
  36. Horn B, Baxter-Lowe LA, Englert L, McMillan A, Quinn M, Desantes K, et al. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Bone Marrow Transplant 2006;37:263-9. https://doi.org/10.1038/sj.bmt.1705240
  37. Muramatsu H, Kojima S, Yoshimi A, Atsuta Y, Kato K, Nagatoshi Y, et al. Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Biol Blood Marrow Transplant 2010;16:231-8. https://doi.org/10.1016/j.bbmt.2009.09.022
  38. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-35. https://doi.org/10.1016/S1470-2045(10)70233-3
  39. Speck B, Bortin MM, Champlin R, Goldman JM, Herzig RH, McGlave PB, et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1984;1:665-8.

Cited by

  1. The treatment of children suffering from chronic myelogenous leukemia: A comparison of the result of treatment with imatinib mesylate and allogeneic hematopoietic stem cell transplantation vol.17, pp.4, 2011, https://doi.org/10.1111/petr.12074
  2. Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia vol.56, pp.8, 2011, https://doi.org/10.3345/kjp.2013.56.8.343
  3. Best treatment option for infantile chronic myeloid leukemia patients: Imatinib or hematopoietic stem cell transplantation? vol.18, pp.3, 2011, https://doi.org/10.1111/petr.12234
  4. Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML vol.21, pp.12, 2020, https://doi.org/10.3390/ijms21124469